Two identical phase 3 studies have shown that 5% imiquimod cream is efficacious and safe for the treatment of typically sized (≤2.0 cm) superficial basal cell carcinomas (sBCCs).1 While most sBCCs are this size, a proportion are larger (≥2 cm).2,3 This study sought to determine if imiquimod would also be efficacious and safe for the treatment of larger sBCC.